Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) were up 6.1% on Monday . The company traded as high as $2.45 and last traded at $2.44, with a volume of 140,395 shares trading hands. The stock had previously closed at $2.30.

A number of analysts have recently weighed in on CBAY shares. HC Wainwright reissued a “buy” rating on shares of CymaBay Therapeutics in a research note on Thursday, May 12th. Zacks Investment Research lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 31st. Finally, Roth Capital started coverage on CymaBay Therapeutics in a research note on Friday, July 1st. They set a “buy” rating for the company.

The firm’s 50 day moving average price is $1.94 and its 200-day moving average price is $1.83. The company’s market capitalization is $57.21 million.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, equities research analysts forecast that CymaBay Therapeutics Inc. will post ($1.20) EPS for the current year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.